Literature DB >> 22077063

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Davide Rossi1, Silvia Rasi, Giulia Fabbri, Valeria Spina, Marco Fangazio, Francesco Forconi, Roberto Marasca, Luca Laurenti, Alessio Bruscaggin, Michaela Cerri, Sara Monti, Stefania Cresta, Rosella Famà, Lorenzo De Paoli, Pietro Bulian, Valter Gattei, Anna Guarini, Silvia Deaglio, Daniela Capello, Raul Rabadan, Laura Pasqualucci, Riccardo Dalla-Favera, Robin Foà, Gianluca Gaidano.   

Abstract

Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077063      PMCID: PMC3257017          DOI: 10.1182/blood-2011-09-379966

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

3.  Predictive value of statistical models.

Authors:  J C Van Houwelingen; S Le Cessie
Journal:  Stat Med       Date:  1990-11       Impact factor: 2.373

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

5.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors:  G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

6.  Regression and recursive partition strategies in the analysis of medical survival data.

Authors:  A Ciampi; J F Lawless; S M McKinney; K Singhal
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

7.  Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia.

Authors: 
Journal:  Br J Haematol       Date:  1990-09       Impact factor: 6.998

8.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

Authors:  H Döhner; K Fischer; M Bentz; K Hansen; A Benner; G Cabot; D Diehl; R Schlenk; J Coy; S Stilgenbauer
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

9.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

10.  Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages.

Authors:  E Montserrat; N Viñolas; J C Reverter; C Rozman
Journal:  Nouv Rev Fr Hematol       Date:  1988
View more
  151 in total

1.  ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2012-01       Impact factor: 9.941

2.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

3.  Activation of the NOTCH1 pathway in chronic lymphocytic leukemia.

Authors:  Valentina Gianfelici
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

4.  NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.

Authors:  Ilaria Del Giudice; Davide Rossi; Sabina Chiaretti; Marilisa Marinelli; Simona Tavolaro; Sara Gabrielli; Luca Laurenti; Roberto Marasca; Silvia Rasi; Marco Fangazio; Anna Guarini; Gianluca Gaidano; Robin Foà
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

5.  Chronic lymphocytic leukemia: looking into the dark side of the genome.

Authors:  R Valdés-Mas; J Gutiérrez-Abril; X S Puente; C López-Otín
Journal:  Cell Death Differ       Date:  2015-11-27       Impact factor: 15.828

6.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Authors:  David M Lucas; Amy S Ruppert; Gerard Lozanski; Gordon W Dewald; Arletta Lozanski; Rainer Claus; Christoph Plass; Ian W Flinn; Donna S Neuberg; Elisabeth M Paietta; John M Bennett; Diane F Jelinek; John G Gribben; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman; John C Byrd; Michael R Grever
Journal:  Leuk Lymphoma       Date:  2015-03-30

7.  Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.

Authors:  Olga Bohn; Takahiro Maeda; Alexander Filatov; Andrea Lunardi; Pier Paolo Pandolfi; Julie Teruya-Feldstein
Journal:  Int J Surg Pathol       Date:  2013-12-10       Impact factor: 1.271

8.  Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.

Authors:  Thirunavukkarasu Velusamy; Nallasivam Palanisamy; Shanker Kalyana-Sundaram; Anagh Anant Sahasrabuddhe; Christopher A Maher; Daniel R Robinson; David W Bahler; Timothy T Cornell; Thomas E Wilson; Megan S Lim; Arul M Chinnaiyan; Kojo S J Elenitoba-Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

10.  Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.

Authors:  Jane Houldsworth; Asha Guttapalli; Venkata Thodima; Xiao Jie Yan; Geetu Mendiratta; Tania Zielonka; Gouri Nanjangud; Weiyi Chen; Sujata Patil; Anthony Mato; Jennifer R Brown; Kanti Rai; Nicholas Chiorazzi; R S K Chaganti
Journal:  Leuk Lymphoma       Date:  2013-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.